에 대한 최신 뉴스 Incyte (NASDAQ:INCY) 주식

INCYTE CORP

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Xpeng g6 SUV

Equities

Large Cap

News

Movers

BEKE

FUTU

INCY

MRNA

RDDT

XPEV

지난주에 가장 저조한 성과를 보인 대형주 10종목은 다음과 같다. KE 홀딩스, 레딧, 인사이트, 제임스 하디, 샤오펑, 뉴코, 부즈 앨런, 텔러스, 푸투, 마이크론

샤오펑·레딧·마이크론 등 지난주 급락한 대형주 (3월 17일~21일)

Why It Matters

Price Target

Markets

Analyst Ratings

Trading Ideas

ALGN

GOOGL

LYFT

PENN

TSLA

화요일(18일) 월가의 상위 애널리스트들이 아래 종목에 대한 전망을 변경했다.  모든 애널리스트의 등급 변경 사항은 애널리스트 등급 페이지에서 확인할 수 있다. 아메리칸 익스프레스, 센티넬원, 펜 엔터테인먼트, GE 버노바, 얼라인, 씨게이트, 리프트, 테슬라, 인사이트, 알파벳

월가 상위 애널리스트 의견 변동: 테슬라 목표주가 320달러?

Temu,App,Seen,On,The,Ipad,Screen.,Temu,Shop,App

BABA

INTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

ULTA

지난 주 가장 성적이 저조했던 대형주들입니다. 당신의 포트폴리오에 포함되어 있나요?1. 타깃 코퍼레이션(NYSE:TGT)의 주식은 회사가 3분기 실적을 발표했으나 예상에 미치지 못하고, 애널리스트들이 주가 목표를 하향 조정한 후 17.83% 하락했다.

타깃, 알리바바 및 테무는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 18일 ~ 11월 22일)

Incyte Corp

Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Equal-Weight and lowers the price target from $69 to $65.

Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $65

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares dipped 15.38% after UBS downgraded the stock from Buy to Neutral and <a href="https://www.benzinga.com/quote/beke/analyst-ratings" target="_blank" rel="noreferrer noopener">announced a price forecast of $24.5</a>.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock fell 9.76%. The stock briefly surged after Google announced an expanded partnership with Reddit, aiming to integrate Reddit content more <a href="https://www.benzinga.com//node/44369039" target="_blank" rel="noreferrer noopener">effectively across Google's products</a>.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock dived 8.75% after reporting topline results from two Phase 3 clinical trials of Povorcitinib in <a href="https://www.benzinga.com//node/44356786" target="_blank" rel="noreferrer noopener">patients with Hidradenitis Suppurativa</a>. William Blair and Guggenheim downgraded the stock, and Truist Securities cut its <a href="https://www.benzinga.com/quote/incy/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $74 to $72</a>.</li>
<li>James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares decreased 8.39%.</li>
<li>XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares dipped 8.13% after the company reported a <a href="https://www.benzinga.com//node/44373548" target="_blank" rel="noreferrer noopener">fourth-quarter adjusted EPS miss</a>.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares decreased 7.63% after the company issued first-quarter adjusted<a href="https://www.benzinga.com//node/44426184" target="_blank" rel="noreferrer noopener"> EPS guidance below estimates</a>.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) stock fell 7.22%. The company said it is entering into a strategic partnership with Shield AI to deliver AI-powered autonomous solutions <a href="https://www.benzinga.com//node/44378015" target="_blank" rel="noreferrer noopener">for the U.S. government</a>.</li>
<li>Telus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) shares decreased 7.07%.</li>
<li>Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) stock declined 7.01%, probably after the People's Bank of China kept the one-year loan prime rate at 3.1% and the five-year rate at 3.6%. Policymakers are navigating how to support economic growth while stabilizing the yuan amid rising trade tensions.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares lost 6.02% last week after Rosenblatt cut its <a href="https://www.benzinga.com/quote/MU/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from</a> $250 to $200. The company reported <a href="https://www.benzinga.com//node/44425486" target="_blank" rel="noreferrer noopener">Q2 financial results</a>.</li>
</ol>
Image by Robert Way via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450329/robinhood-roku-and-shopify-are-among-top-10-large-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
</ul>

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs cut American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) price target from $367 to $330. Goldman Sachs analyst Ryan Nash maintained a Buy rating. American Express shares closed at $264.38 on Monday. See how other <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">analysts view this stock.</a></li>
<li>Morgan Stanley slashed the price target for SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from $27 to $20. Morgan Stanley analyst Hamza Fodderwala maintained an Equal-Weight rating. SentinelOne shares closed at $18.91 on Monday. <a href="https://www.benzinga.com/quote/S/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) price target from $22 to $19. Stifel analyst Steven Wieczynski maintained a Hold rating. PENN Entertainment shares closed at $17.26 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/PENN/analyst-ratings">view this stock</a>.</li>
<li>RBC Capital cut the price target for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from $453 to $445. RBC Capital analyst Christopher Dendrinos maintained an Outperform rating. GE Vernova shares closed at $331.96 on Monday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) from $270 to $235. Piper Sandler analyst Jason Bednar reiterated an Overweight rating. Align Technology shares closed at $169.59 on Monday. <a href="https://www.benzinga.com/quote/ALGNX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) price target from $125 to $115. Citigroup analyst Asiya Merchant maintained a Buy rating. Seagate shares settled at $90.51 on Monday. <a href="https://www.benzinga.com/quote/STX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital cut Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) price target from $23 to $20. Loop Capital analyst Rob Sanderson maintained a Buy rating. Lyft shares closed at $12.03 on Monday. <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) price target from $74 to $72. Truist Securities analyst Srikripa Devarakonda maintained a Hold rating. Incyte shares closed at $62.01 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital cut the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $440 to $320. RBC Capital analyst Tom Narayan maintained an Outperform rating. Tesla shares settled at $238.01 on Monday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $220 to $202. Keybanc analyst Justin Patterson maintained an Overweight rating. Alphabet shares closed at $164.29 on Monday. <a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Tesla To $320? Here Are 10 Top Analyst Forecasts For Tuesday

WIIM

Incyte shares are trading lower after William Blair and Guggenheim downgraded the stock and Truist Securities cut its price target from $74 to $72.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Lauren Lieberman downgraded the rating for PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and lowered the price target from $168 to $156. PepsiCo shares closed at $151.34 on Monday. <a href="https://www.benzinga.com/quote/pep/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim analyst Michael Schmidt downgraded Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintained the price target of $92. Incyte shares closed at $62.01 on Monday. <a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith downgraded TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) from Hold to Underperform and lowered the price target from $2.3 to $0.5. TPI Composites shares closed at $1.20 on Monday. <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Steven Fisher downgraded PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announced a $108 price target. PACCAR shares closed at $101.17 on Monday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Y Katherine Xu downgraded the rating for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform. Incyte shares closed at $62.01 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/ONCY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PEP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-1024x571.png" alt="" class="wp-image-829930" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Downgrades

PCAR

TPIC

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and lowers the price target from $74 to $72.

Truist Securities Maintains Hold on Incyte, Lowers Price Target to $72

Guggenheim analyst Michael Schmidt downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintains the price target from $92 to $92.

Guggenheim Downgrades Incyte to Neutral, Maintains Price Target to $92

William Blair analyst Y Katherine Xu downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform.

William Blair Downgrades Incyte to Market Perform

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)&nbsp;released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hidradenitis suppurativa (HS)</a>.
Hidradenitis suppurativa (HS), also known as acne inversa, is&nbsp;a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead to abscesses and scarring.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44245346/eli-lilly-incyte-partnered-fda-approved-drug-shows-encouraging-efficacy-in-adolescent-patients-with-patchy-hair-loss" rel="noreferrer noopener">Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss</a>
STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).
A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44352766/incyte-announces-positive-topline-results-from-two-phase-3-clinical-trials-of-povorcitinib-in-pati" rel="noreferrer noopener">draining tunnel count</a>.
The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:
<ul>
<li>STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024]; 75 mg: 40.6% vs 29.7% [P=0.022].</li>
<li>STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004]; 75 mg: 42.3% vs. 28.6% [P=0.003].</li>
</ul>
Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo:
<ul>
<li>STOP-HS1: 45 mg: 34.2% vs. 21.9% [P=0.096]; 75 mg: 37.8% vs. 21.9% [P=0.037].</li>
<li>STOP-HS2: 45 mg: 45.0% vs. 19.5% [P=0.001]; 75 mg: 40.0% vs. 19.5% [P=0.005].</li>
</ul>
In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares,&nbsp;&gt;3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30.
Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.
Last week, Incyte revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis, a chronic skin condition characterized by <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44229321/incyte-releases-mixed-data-from-late-stage-opzelura-studies-in-skin-disease-characterized-by-itchy-firm-lumps" rel="noreferrer noopener">very itchy firm lumps</a>.
Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains</a></li>
</ul>

Biotech

Health Care

General

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.
Incyte shares dipped 15.3% to $57.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 12.1% to $44.01 in pre-market trading after gaining around 7% on Friday.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) fell 3.8% to $8.71 in pre-market trading.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) slipped 3.3% to $7.62 in pre-market trading.</li>
<li>Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) fell 3% to $6.77 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1% to $ 247.77 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying">IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

AFRM

KMDA

NEOG

OMER

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Incyte Corporation shares are trading lower after the company announced the results from its phase 3 STOP-HS clinical trial program of Povorcitinib for severe hidradenitis suppurativa.

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares increased by 107.6% to $5.19 during Monday's pre-market session. The company's market cap stands at $7.3 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 39.89% to $1.08. The company's market cap stands at $1.0 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares rose 19.85% to $1.63. The company's market cap stands at $258.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares moved upwards by 19.23% to $3.1. The company's market cap stands at $340.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares increased by 17.47% to $4.1. The market value of their outstanding shares is at $19.8 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 14.63% to $0.35. The market value of their outstanding shares is at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares decreased by 25.0% to $2.55 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock decreased by 22.29% to $0.55. The market value of their outstanding shares is at $41.1 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) shares fell 14.9% to $57.75. The market value of their outstanding shares is at $11.1 billion. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 12.55% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) shares declined by 11.65% to $9.71. The company's market cap stands at $425.0 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined by 9.46% to $0.34. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ANNX

CAPS

CNTX

MAZE

PALI

REVB

SHPH

SNTI

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/DTIL">pre-market trading</a>.
Precision BioSciences reported clearance of investigational new drug application by the U.S. FDA for first-in-class PBGENE-HBV designed to eliminate root cause of chronic hepatitis B.
Precision BioSciences shares climbed 10.8% to $5.58 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) gained 42.3% to $3.11 in pre-market trading.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) rose 36.7% to $0.1532 in pre-market trading after dipping 20% on Friday.</li>
<li>SES AI Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SES#NASDAQ">SES</a>) gained 29.1% to $0.5675 in pre-market trading after gaining 9% on Friday.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) gained 27.4% to $0.9837 in pre-market after gaining 13% on Friday.</li>
<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) gained 21.3% to $1.65 in pre-market trading after jumping 19% on Friday.</li>
<li>Inuvo, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INUV#NYSE">INUV</a>) gained 18.2% to $0.45 in pre-market trading.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) gained 16.5% to $0.9076 in pre-market trading.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 15% to $8.15 after jumping 29% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) rose 11% to $1.61 in pre-market trading after jumping 14% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fold Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLD#NASDAQ">FLD</a>) shares fell 18.8% to $6.00 in pre-market trading after gaining around 8% on Friday.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 15.3% to $57.50 in pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.</li>
<li>Planet Green Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLAG#NYSE">PLAG</a>) dipped 14.4% to $1.71 in pre-market trading.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) declined 14.1% to $2.92 in pre-market trading.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Linkage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares tumbled 13.5% to $0.1537 in pre-market trading after dipping over 22% on Friday.</li>
<li>Polar Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares fell 12.3% to $2.36 in pre-market trading.</li>
<li>Aspira Women&#8217;s Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) fell 10.8% to $0.1250 in today's pre-market trading after dipping over 8% on Friday. Aspira Women&#8217;s Health recently announced closing of $1.37 million private placement of convertible notes.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44350021/science-applications-international-getty-images-and-3-stocks-to-watch-heading-into-monday">Science Applications International, Getty Images And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
Photo: Shutterstock

DRCT

DTIL

INUV

KULR

LGCB

NAOV

PLAG

POLA

QUBT

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested
- Favorable safety profile, with no safety concerns

Incyte Announced Topline Results From Its Phase 3 STOP-HS Clinical Trial Program Of Povorcitinib For Severe Hidradenitis Suppurativa, Both STOP-HS1 And STOP-HS2 Studies Met Their Primary Endpoint At Both Tested Doses

In the preceding three months, 6 analysts have released ratings for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $75.0, a high estimate of $88.00, and a low estimate of $68.00. A decline of 1.32% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741701634_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$77.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Incyte analyst ratings.</a>
<h2>Discovering Incyte: A Closer Look</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Breaking Down Incyte's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Incyte displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 16.32%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 17.07%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Incyte's ROE excels beyond industry benchmarks, reaching 6.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Incyte's ROA stands out, surpassing industry averages. With an impressive ROA of 3.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Incyte's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Citizens Capital Markets analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Market Perform to Market Perform.

Reiteration

Citizens Capital Markets Reiterates Market Perform on Incyteto Market Perform

On Saturday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;and Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">eyelashes at Week 36</a>.
Findings from the Phase 3 BRAVE-AA-PEDS study were presented at the American Academy of Dermatology.
AA is an immune system condition that causes patchy hair loss on the scalp, face, and sometimes other body areas, which can <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44209669/lillys-baricitinib-delivered-high-rates-of-hair-regrowth-for-adolescents-with-severe-alopecia-area" rel="noreferrer noopener">progress over time</a>.
At Week 36:
<ul>
<li>60.0% of patients receiving baricitinib 4 mg and 36.9% of patients receiving baricitinib 2 mg saw at least a 50% improvement in their disease compared to 5.7% on placebo.</li>
<li>42.4% of patients receiving baricitinib 4 mg and 27.4% receiving baricitinib 2 mg achieved 80% or more scalp hair coverage, compared to 4.5% on placebo.</li>
<li>36.5% of patients receiving baricitinib 4 mg and 21.4% of patients receiving baricitinib 2 mg had 90% or more scalp hair coverage compared to 2.3% on placebo.</li>
<li>50.0% of patients receiving baricitinib 4 mg and 24.1% of patients receiving baricitinib 2 mg achieved significant eyebrow regrowth compared to 0% on placebo.</li>
<li>42.9% of patients receiving baricitinib 4 mg achieved significant eyelash regrowth, and 25.5% receiving baricitinib 2 mg saw improved eyelash regrowth, compared to 14.0% on placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44194539/eli-lillys-single-monthly-maintenance-shot-of-eczema-drug-shows-completely-clear-skin-at-3-years-in-50-of-trial-patients" rel="noreferrer noopener">Eli Lilly&#8217;s Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients</a>
Results achieved by adolescents at 36 weeks were comparable to those achieved by adults after 52 weeks of treatment, suggesting that hair regrowth may be faster in&nbsp;adolescents than in adults.
In the&nbsp;BRAVE-AA1 and BRAVE-AA2 studies, 40.9% of adult patients treated with baricitinib 4 mg and 21.2% of patients treated with baricitinib 2 mg achieved 80% or more scalp hair coverage at Week 52.
In 2022, the U.S. Food and Drug Administration (FDA) approved baricitinib, also known as Olumiant, for adult patients with severe AA.
Price Action: LLY stock is down 0.57% at $825.01, and INCY stock is up 0.89% at $71.76 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44242667/faraday-future-forays-into-new-york-ev-market-with-ff-91-20-launch" target="_blank" rel="noreferrer noopener">Faraday Future&#8217;s Big Apple Bet: Plans NY Expansion For Growth &amp; Brand Visibility</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

On Saturday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis (PN), a chronic skin condition characterized by very itchy firm lumps.
The data were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43597062/incyte-records-15-jump-in-2024-sales-on-strong-jakafi-opzelura-sales-says-2025-to-be-catalyst-rich-including-four-launches" rel="noreferrer noopener">Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches</a>
The TRuE-PN1 study met its primary endpoint, demonstrating that significantly more PN patients who applied ruxolitinib cream 1.5% versus vehicle control achieved a ≥4-point improvement from baseline in Worst-Itch Numeric Rating Scale (WI-NRS4) at Week 12 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44209194/incyte-announces-results-of-phase-3-clinical-trials-evaluating-ruxolitinib-cream-1-5-opzelura-in-p" rel="noreferrer noopener">(44.6% vs 20.6%)</a>.
Significant itch improvements were observed with ruxolitinib cream 1.5% versus vehicle control at Day 7 (22.4% vs. 8.0%), with numerical improvements versus vehicle control reported at earlier timepoints. Additionally, the TRuE-PN1 study met all key secondary endpoints, including:
<ul>
<li>Significantly more patients who applied ruxolitinib cream 1.5% versus vehicle control achieved an Investigator's Global Assessment for Stage of Chronic Prurigo Treatment Success (IGA-CPG-S-TS) at Week 12 (15.8% vs 3.9%).</li>
<li>Significantly more patients who applied ruxolitinib cream 1.5% versus vehicle control achieved overall treatment success (11.9% vs 2.9%).</li>
<li>Significantly more patients treated with ruxolitinib cream 1.5% versus vehicle control also achieved WI-NRS4 at Week 4 (29.7% vs 12.7%).</li>
</ul>
Additionally, topline data from the Phase 3 TRuE-PN2 clinical trial demonstrated a positive trend across all key secondary endpoints at Day 7 (nominal P-value &lt;0.05 for both).
While the primary endpoint favored ruxolitinib cream 1.5% versus vehicle, it did not reach statistical significance due to the high placebo response.
William Blair analyst Matt Phipps sees the TRuE-PN study results as disappointing, but they don't impact Incyte valuation since the model didn't factor in Opzelura's potential for PN. The company considers PN a smaller market for Opzelura, generating less than $1 billion, compared to its use for atopic dermatitis and vitiligo.
Price Action: INCY stock is up 0.92% at $71.44 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44224649/trevi-therapeutics-reveals-positive-data-from-mid-stage-study-for-chronic-cough-candidate-stock-jumps" target="_blank" rel="noreferrer noopener">Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps</a></li>
</ul>

Analyst Color

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

<ul>
<li>Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg</li>
<li>Patients treated with&nbsp;baricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo</li>
<li>Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need</li>
</ul>

Reported Saturday, Lilly And Incyte Present Late-Breaking Phase 3 Data Showing Baricitinib Significantly Improves Scalp, Eyebrow, And Eyelash Regrowth In Teens With AA

Incyte And Genesis Therapeutics Enter Into Strategic AI-Focused Research Collaboration

Press Releases

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Incyte to Present at Upcoming Investor Conferences

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Contracts

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

TSX:GUD

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

Truist Securities

Guggenheim

RBC Capital

Citigroup

Incyte Pharms

지난주에 가장 저조한 성과를 보인 대형주 10종목은 다음과 같다.
<ol>
<li>KE 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>): 주가는 15.38% 하락했다. UBS가 매수에서 중립으로 투자의견을 하향 조정하고 <a href="https://www.benzinga.com/quote/beke/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 24.5달러로 발표</a>한 후였다.</li>
<li>레딧 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>): 주가는 지난주 9.76% 하락했다. 구글이 레딧과의 파트너십 확대를 발표하여 레딧 콘텐츠를 <a href="https://www.benzinga.com//node/44369039" target="_blank" rel="noreferrer noopener">구글 제품 전반에 더 효과적으로 통합</a>할 계획을 발표한 후 잠시 급등했지만 주간 하락했다.</li>
<li>인사이트 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): 주가는 8.75% 하락했다. 이는 포보시티닙(Povorcitinib)의 3상 임상시험 결과가 <a href="https://www.benzinga.com//node/44356786" target="_blank" rel="noreferrer noopener">히드라데니티스 수퍼라티바(Hidradenitis suppurativa) 증상 환자</a>를 대상으로 발표된 후 발생한 일이다. 윌리엄 블레어와 구겐하임이 주식을 하향 조정하였고, 트루이스트 증권은 목표주가를 <a href="https://www.benzinga.com/quote/incy/analyst-ratings" target="_blank" rel="noreferrer noopener">74달러에서 72달러로 하향 조정</a>했다.</li>
<li>제임스 하디 인더스트리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>): 주가는 8.39% 하락했다.</li>
<li>샤오펑 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>): 주가는 8.13% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/44373548" target="_blank" rel="noreferrer noopener">4분기 조정 EPS 실적이 예상치를 밑돌았다</a>고 보고한 후 발생한 일이다.</li>
<li>뉴코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): 주가는 7.63% 하락했다. 회사가 1분기 조정 <a href="https://www.benzinga.com//node/44426184" target="_blank" rel="noreferrer noopener">EPS 가이던스를 예상치 이하로 발표</a>한 후 하락했다.</li>
<li>부즈 앨런 해밀턴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>): 주가는 7.22% 하락했다. 회사는 쉴드AI(Shield AI)와의 전략적 파트너십을 통해 <a href="https://www.benzinga.com//node/44378015" target="_blank" rel="noreferrer noopener">미 정부를 위한 AI 기반 자율 솔루션</a>을 제공할 것이라고 발표했다.</li>
<li>텔러스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>): 주가는 7.07% 하락했다.</li>
<li>푸투 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>): 주가는 7.01% 하락했다. 이는 중국 인민은행이 1년 만기 대출 우대 금리를 3.1%, 5년 만기 금리를 3.6%로 동결했기 때문일 수 있다. 정책 입안자들은 무역 갈등 심화 속에서 위안화를 안정시키면서 경제 성장을 지원하는 방법을 모색하고 있다.</li>
<li>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): 주가는 6.02% 하락했다. 이는 로젠블랫이 <a href="https://www.benzinga.com/quote/MU/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 250달러에서 200달러로 하향 조정</a>한 후 발생한 일이다. 회사는 <a href="https://www.benzinga.com//node/44425486" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표했다.</li>
</ol>
이미지 제공: Robert Way via Shutterstock
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A1%9C%EB%B9%88%ED%9B%84%EB%93%9C%EB%A1%9C%EC%BF%A0%EC%87%BC%ED%94%BC%ED%8C%8C%EC%9D%B4-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EA%B8%89%EB%93%B1%ED%95%9C-%EB%8C%80%ED%98%95%EC%A3%BC-3/">로빈후드·로쿠·쇼피파이 등 지난주 급등한 대형주 (3월 17일~21일)</a>
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일(18일) 월가의 상위 애널리스트들이 아래 종목에 대한 전망을 변경했다.  모든 애널리스트의 등급 변경 사항은 <a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noopener">애널리스트 등급 페이지</a>에서 확인할 수 있다.
<ul>
<li>골드만삭스는 아메리칸 익스프레스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) 목표주가를 367달러에서 330달러로 하향 조정했다. 골드만삭스 애널리스트 라이언 내쉬는 매수 등급을 유지했다. 아메리칸 익스프레스 주식은 월요일에 264.38달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/AXP/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>모건스탠리는 센티넬원(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) 목표주가를 27달러에서 20달러로 대폭 하향 조정했다. 모건스탠리 애널리스트 함자 포더왈라는 중립 등급을 유지했다. 센티넬원 주식은 월요일에 18.91달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/S/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>스티펠은 펜 엔터테인먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) 목표주가를 22달러에서 19달러로 하향 조정했다. 스티펠 애널리스트 스티븐 비첸스키는 보유 등급을 유지했다. 펜 엔터테인먼트 주식은 월요일에 17.26달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/PENN/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>RBC 캐피털은 GE 버노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) 목표주가를 453달러에서 445달러로 하향 조정했다. RBC 캐피털 애널리스트 크리스토퍼 덴드리노스는 시장수익률 상회 등급을 유지했다. GE 버노바 주식은 월요일에 331.96달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/GEV/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>파이퍼 샌들러는 얼라인 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) 목표주가를 270달러에서 235달러로 하향 조정했다. 파이퍼 샌들러 애널리스트 제이슨 베드나르는 비중확대 등급을 재확인했다. 얼라인 테크놀로지 주식은 월요일에 169.59달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/ALGNX/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>씨티그룹은 씨게이트 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) 목표주가를 125달러에서 115달러로 하향 조정했다. 씨티그룹 애널리스트 아시아 머천트는 매수 등급을 유지했다. 씨게이트 주식은 월요일에 90.51달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/STX/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>루프 캐피털은 리프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) 목표주가를 23달러에서 20달러로 하향 조정했다. 루프 캐피털 애널리스트 롭 샌더슨은 매수 등급을 유지했다. 리프트 주식은 월요일에 12.03달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>트루이스트 증권은 인사이트 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) 목표주가를 74달러에서 72달러로 하향 조정했다. 트루이스트 증권 애널리스트 스리크리파 데바라콘다는 보유 등급을 유지했다. 인사이트 주식은 월요일에 62.01달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/INCY/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>RBC 캐피털은 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) 목표주가를 440달러에서 320달러로 하향 조정했다. RBC 캐피털 애널리스트 톰 나라얀은 시장수익률 상회 등급을 유지했다. 테슬라 주식은 월요일에 238.01달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>키뱅크는 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) 목표주가를 220달러에서 202달러로 하향 조정했다. 키뱅크 애널리스트 저스틴 패터슨은 비중확대 등급을 유지했다. 알파벳 주식은 월요일에 164.29달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
</ul>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난 주 가장 성적이 저조했던 대형주들입니다. 당신의 포트폴리오에 포함되어 있나요?
1. 타깃 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)의 주식은 회사가 3분기 실적을 발표했으나 예상에 미치지 못하고, 애널리스트들이 <a href="https://www.benzinga.com/node/42117500" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>한 후 17.83% 하락했다.
2. 테무의 모회사인 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 회사가 <a href="https://www.benzinga.com/node/42111158" target="_blank" rel="noreferrer noopener">예상보다 저조한 재무결과</a>를 발표하고 애널리스트들이 <a href="https://www.benzinga.com/quote/pdd/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>한 후 12.22% 급락했다.
3. ZTO 익스프레스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>)의 주식은 회사가 3분기 실적을 발표하고 FY24 <a href="https://www.benzinga.com/node/42076268" target="_blank" rel="noreferrer noopener">소포 물량 가이던스를 하향 조정</a>한 후 8.50% 하락했다.
4. 테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)의 주식은 투자은행 레이먼드 제임스(Raymond James)가 주식을 <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">강력 매수에서 아웃퍼폼으로 하향 조정</a>한 후 7.54% 하락했다.
5. 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식은 버크셔 해서웨이가 <a href="https://www.benzinga.com/node/42013172">주식 보유 비중을 축소</a>한 후 7.34% 하락했다.
6. 인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)의 주식은 회사가 <a href="https://www.benzinga.com/node/42123997" target="_blank" rel="noreferrer noopener">2분기 실적을 발표</a>한 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/intu/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>하여 6.94% 하락했다.
7. 노키아 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>)의 주식은 회사가 바티 에어텔(<a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Bharti Airtel</a>)과 인도에서 수년간 수십억 달러 규모의 계약 연장을 확보했다고 발표한 후 6.28% 하락했다.
8. 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 주식은 회사가 자본을 조달하고 기존 부채를 상환하며 <a href="https://www.benzinga.com/node/42032495" target="_blank" rel="noreferrer noopener">진행 중인 자사주 매입 프로그램</a>을 지원하기 위해 미국 달러 및 중국 위안화 채권을 발행할 계획이라고 발표한 후 6.16% 하락했다.
9. 방코 산탄데르(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>)의 주식은 5.60% 하락했다.
10. 인사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)의 주식은 회사가 MRGPRX4 (INCB000547)에 대한 2상 연구 데이터를 발표하고 <a href="https://www.benzinga.com/node/42070590" target="_blank" rel="noreferrer noopener">추가 개발을 지원하지 않는다고 발표</a>한 후 5.47% 하락했다.
사진 출처: Shutterstock
다음 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EB%B0%8F-%EC%8B%AC%EB%B3%B4%ED%8B%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">슈퍼 마이크로 및 심보틱 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 18일 – 11월 22일)</a>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

기술주가 <a href="https://www.benzinga.com/tech" target="_blank" rel="noopener" data-google-interstitial="false">시장 상승세를 주도함</a>에 따라 나스닥 100 지수는 목요일에 4일 연속 올랐다. 이 지수는 0.6% 오른 19,576포인트로 마감하며 사상 최고치를 경신했다.
S&amp;P 500 지수도 4일 연속 올랐다. 목요일 이 지수는 0.2% 상승해 사상 최고치인 5,433포인트를 기록했다. <a href="https://www.benzinga.com/markets/equities/24/06/39310762/producer-inflation-rise-less-than-expected-jobless-claims-soar-thursdays-economic-digest" target="_blank" rel="noopener" data-google-interstitial="false">실망스러운 실업 수당 청구 데이터</a>로 인한 오전 하락세에서 반등했다.
오후에는 재닛 옐런 미국 재무장관이 디스인플레이션의 지속적인 진전에 대해 낙관론을 표명한 후 트레이더들이 위험 자산에 대한 신뢰를 회복했다. 옐런은 노동시장 압박 완화를 언급하면서도 고용시장은 여전히 ​​강세를 유지하고 있다고 강조했다.
시장은 9월 금리 인하 가능성이 70%에 가까울 것으로 예상하고 있으며, 현재 연말까지 50bp(베이시스포인트) 이상의 인하를 책정하고 있다. 이는 두번의 금리 인하에 해당한다.
S&amp;P 500의 11개 부문 중 목요일 실적에서는 기술 부문이 1% 상승했고 그 뒤를 이어 부동산 부문이 0.5% 상승했다. 두 가지 모두 금리 인하에 대한 기대가 높아지면서 뒷받침되었다.
에너지 부문은 0.9% 감소해 가장 큰 부진을 겪었고, 통신 서비스 부문이 0.7% 감소해 그 뒤를 이었다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>섹터</th>
<th>1일 변동률</th>
</tr>
</thead>
<tbody>
<tr>
<td>기술을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>1.02%</td>
</tr>
<tr>
<td>부동산을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>0.52%</td>
</tr>
<tr>
<td>유틸리티를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>0.19%</td>
</tr>
<tr>
<td>소비자 선택 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>0.13%</td>
</tr>
<tr>
<td>기본소비재를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>0.12%</td>
</tr>
<tr>
<td>소재를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>-0.03%</td>
</tr>
<tr>
<td>헬스케어를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>-0.04%</td>
</tr>
<tr>
<td>파이낸셜 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>-0.10%</td>
</tr>
<tr>
<td>산업을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>-0.64%</td>
</tr>
<tr>
<td>통신 서비스를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>-0.73%</td>
</tr>
<tr>
<td>에너지를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>-0.93%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">나스닥 100의 상승종 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>1,679.29</td>
<td>12.29%</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>129.37</td>
<td>3.33%</td>
</tr>
<tr>
<td>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>182.33</td>
<td>2.84%</td>
</tr>
<tr>
<td>엑셀론 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>)</td>
<td>35.40</td>
<td>1.86%</td>
</tr>
<tr>
<td>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)</td>
<td>143.08</td>
<td>1.66%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">나스닥 100 하락종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>7.31</td>
<td>-6.40%</td>
</tr>
<tr>
<td>몽고DB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)</td>
<td>218.14</td>
<td>-4.85%</td>
</tr>
<tr>
<td>아틀라시안 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)</td>
<td>156.04</td>
<td>-4.17%</td>
</tr>
<tr>
<td>Z스케일러 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)</td>
<td>181.00</td>
<td>-4.15%</td>
</tr>
<tr>
<td>시리우스 XM 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)</td>
<td>2.53</td>
<td>-3.93%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 상승종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>수퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>871.16</td>
<td>12.45%</td>
</tr>
<tr>
<td>브로드컴</td>
<td>1,678.90</td>
<td>12.26%</td>
</tr>
<tr>
<td>아리스타 네트웍스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>)</td>
<td>331.67</td>
<td>6.53%</td>
</tr>
<tr>
<td>인사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>62.68</td>
<td>4.57%</td>
</tr>
<tr>
<td>코보 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)</td>
<td>113.36</td>
<td>4.27%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 하락종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)</td>
<td>10.35</td>
<td>-6.92%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리</td>
<td>7.31</td>
<td>-6.40%</td>
</tr>
<tr>
<td>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>)</td>
<td>60.15</td>
<td>-4.93%</td>
</tr>
<tr>
<td>제네락 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>136.17</td>
<td>-4.58%</td>
</tr>
<tr>
<td>앨버말 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>108.23</td>
<td>-3.92%</td>
</tr>
</tbody>
</table>
</figure>
지금 읽기: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/06/39317123/goldman-sachs-reaffirms-september-rate-cut-forecast-downplays-feds-hawkish-surprise">골드만삭스, 9월 금리인하 전망 재확인, 연준의 &#8216;매파적 서프라이즈&#8217; 경시</a>
이미지: 셔터스톡

Government

Macro Notification

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Tech

ETFs

ANET

AVGO

ETSY

GNRC

NVDA

PARA

QRVO

SIRI

SMCI

TEAM

XLRE

나스닥 100, S&P 500은 기술주가 우위를 되찾으며 사상 최고치로 마감: 상승주와 하락주

Comments

Incyte

뉴스

에 대한 최신 뉴스 Incyte (NASDAQ:INCY) 주식

일요일, 3월 23, 2025

수요일, 3월 19, 2025

일요일, 11월 24, 2024

목요일, 6월 13, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌